Using the industry peer median EV/EBITDA multiple (trailing + forward), Caris Life Sciences, Inc. (CAI) has a fair value of $0.49 based on 2 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Caris Life Sciences, Inc.CAI | 26,653 | 2305.3x | 1858.1x |
| Halozyme Therapeutics, Inc. | 7,445 | 8.1x | 6.4x |
| Corcept Therapeutics Incorporated | 4,345 | 61.9x | 52.4x |
| Industry Median | 35.0x | 29.4x | |
| (*) EBITDA | 11 | 14 | |
| = Enterprise Value | 398 | 415 | |
| (-) Net Debt | -419 | -419 | |
| Equity Value | 817 | 834 | |
| (/) Outstanding shares | 1,672 | 1,672 | |
| Fair Price | $0 | $0 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Caris Life Sciences, Inc. (CAI) has a fair value of $5.09 based on 7 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Caris Life Sciences, Inc.CAI | 26,653 | 32.3x | 26.0x |
| Moderna, Inc. | 19,261 | 9.6x | 8.9x |
| Madrigal Pharmaceuticals, Inc. | 12,247 | 12.9x | 8.4x |
| Jazz Pharmaceuticals plc | 11,503 | 3.6x | 3.5x |
| Cytokinetics, Incorporated | 7,998 | 95.4x | 92.1x |
| Halozyme Therapeutics, Inc. | 7,445 | 5.2x | 4.2x |
| Rhythm Pharmaceuticals, Inc. | 5,938 | 32.3x | 21.3x |
| Corcept Therapeutics Incorporated | 4,345 | 5.6x | 4.7x |
| Industry Median | 9.6x | 8.4x | |
| (*) Revenue | 812 | 1,007 | |
| = Enterprise Value | 7,762 | 8,435 | |
| (-) Net Debt | -419 | -419 | |
| Equity Value | 8,181 | 8,854 | |
| (/) Outstanding shares | 1,672 | 1,672 | |
| Fair Price | $5 | $5 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.